Transgene unveils myvac (TM), an individualized immunotherapy against solid tumors
information fournie par Boursorama 24/09/2018 à 17:45
Transgene unveils myvac (TM), an individualized immunotherapy against solid tumors
•myvac (TM) is a viral vector-based, individualized immunotherapy that has been developed to target solid tumors
•myvac (TM) stimulates the patient’s immune system to recognize and destroy tumors using their own cancer specific genetic mutations
•myvac (TM) is a highly innovative approach that combines the use of the tumor’s neoantigens with the Transgene’s viral vector expertise
•First patient to be treated in 2019
.../...